Why Novavax Is Crushing It This Week
Novavax (NASDAQ: NVAX) is absolutely crushing it this week. Shares of the vaccine maker were up 29.9% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence.
Investors appear to be jumping back on the Novavax bandwagon after a couple of recent positive developments. The U.S. Food and Drug Administration (FDA) announced last week that it plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for COVID-19 vaccine NVX-CoV2373. Also, on Wednesday Novavax requested expanded EUA in Great Britain for its vaccine in adolescents ages 12 to 17.
To be sure, one week of strong gains doesn't make up for the extended slump the vaccine stock has experienced. Novavax's shares are still nearly 80% below the high set in September 2021.
Source Fool.com
